Abstract
In this article, the synergistic effects of WP 631 and epothilone B (Epo B) combination in human ovarian cancer cells (SKOV-3) cells are investigated and the reasons for the exact mechanisms of action of both drugs co-administered are explained. Compared with single drugs, the combination treatment significantly enhances apoptosis as confirmed by increases in caspases (-8, -9, -3) activity, ROS level and DNA damage and decreases in mitochondrial membrane potential. The combination of the compounds activated both caspase - 8 and -9, indicates that both pathways of apoptosis, extrinsic (induced by the effect of Epo B) and intrinsic (triggered mainly by WP 631) participate in the proposed treatment. Thus, the results of this study strongly suggest a synergistic action of the combined treatment with WP 631 and Epo B in SKOV-3 cells death induction.
Keywords: Apoptosis, epothilone B, ovarian cancer, synergism, WP 631.
Anti-Cancer Agents in Medicinal Chemistry
Title:Caspases and ROS - Dependent Mechanism of Action Mediated by Combination of WP 631 and Epothilone B
Volume: 14 Issue: 9
Author(s): Aneta Rogalska, Barbara Bukowska and Agnieszka Marczak
Affiliation:
Keywords: Apoptosis, epothilone B, ovarian cancer, synergism, WP 631.
Abstract: In this article, the synergistic effects of WP 631 and epothilone B (Epo B) combination in human ovarian cancer cells (SKOV-3) cells are investigated and the reasons for the exact mechanisms of action of both drugs co-administered are explained. Compared with single drugs, the combination treatment significantly enhances apoptosis as confirmed by increases in caspases (-8, -9, -3) activity, ROS level and DNA damage and decreases in mitochondrial membrane potential. The combination of the compounds activated both caspase - 8 and -9, indicates that both pathways of apoptosis, extrinsic (induced by the effect of Epo B) and intrinsic (triggered mainly by WP 631) participate in the proposed treatment. Thus, the results of this study strongly suggest a synergistic action of the combined treatment with WP 631 and Epo B in SKOV-3 cells death induction.
Export Options
About this article
Cite this article as:
Rogalska Aneta, Bukowska Barbara and Marczak Agnieszka, Caspases and ROS - Dependent Mechanism of Action Mediated by Combination of WP 631 and Epothilone B, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (9) . https://dx.doi.org/10.2174/1871520614666140608150807
DOI https://dx.doi.org/10.2174/1871520614666140608150807 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant-Derived Bioactive Compounds Produced by Endophytic Fungi
Mini-Reviews in Medicinal Chemistry Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry Management of Fallopian Tube Cancer
Reviews on Recent Clinical Trials Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets A Phase I Study of OMN54 (Aneustat™) in Patients with Advanced Malignancies
Clinical Cancer Drugs Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry